Bristol Myers drops Orum-partnered drug candidate from pipeline
Bristol Myers Squibb has halted development of BMS-986497/ORM-6151, a Phase 1 antibody-drug conjugate from its partnership with Orum Therapeutics. The company disclosed the decision in a regulatory filing on Thursday. The candidate was part of a deal that included a $100 million upfront payment.
The decision to drop BMS-986497/ORM-6151 marks a setback for Bristol Myers Squibb’s oncology pipeline, particularly within the antibody-drug conjugate space. The candidate, which had entered Phase 1 testing, was a key asset from a partnership with Orum Therapeutics that involved a $100 million upfront payment. Regulatory filings indicate the company has now removed the drug from its development portfolio, though no reasons were provided. Such early-stage discontinuations are common in drug development, where safety, efficacy, or strategic fit can shift priorities. The move may also affect Orum’s future collaboration prospects, as milestone payments tied to the program are unlikely to materialize.
This development could ripple through the biotech investment community, as partnerships with large pharma often hinge on early-stage data. Orum may face reduced valuation or need to seek new partners, while Bristol Myers reallocates resources to other candidates. Patients awaiting novel cancer therapies may see no direct impact, but the loss of one investigational drug underscores the high attrition rate in oncology. For researchers and competitors, it signals caution about similar mechanisms, though broader progress in the field remains unaffected.